# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 51-60 of 573 results.
Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Nov 05, 2019
First Received: Apr 01, 2015
Disease(s): Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Intervention(s): Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma
Status: Recruiting
Last Changed: Oct 01, 2019
First Received: Jun 21, 2019
Disease(s): Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma
Intervention(s): CAR-CD19 T Cells
Locations: Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma
Status: Not yet recruiting
Last Changed: Apr 12, 2019
First Received: Mar 19, 2019
Disease(s): Lymphoma, B-Cell
Intervention(s): TAC01-CD19
Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma
Status: Recruiting
Last Changed: Nov 22, 2019
First Received: Nov 22, 2019
Disease(s): Lymphoma, B-Cell
Intervention(s): HZ-A-018
Locations: First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Dec 10, 2019
First Received: May 13, 2015
Disease(s): Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Intervention(s): Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Laboratory Biomarker Analysis, Melphalan, Pharmacogenomic Study, Placebo Administration
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
Alaska Women's Cancer Care, Anchorage, Alaska, United States
... and 268 other locations.
Indolent Non Follicular Lymphomas Prognostic Project
Status: Recruiting
Last Changed: Dec 31, 2018
First Received: Sep 19, 2016
Disease(s): Indolent B-Cell Lymphomas
Intervention(s): Any treatment, watch and wait policy included
Locations: Vienna Univ Med Int I, Vienna, Austria
Center of Hematology and Hemotherapy, UNICAMP, University of Campinas, Campinas, Brazil
Hospital das Clínicas Universidade Federal de Goiás, Goiania, Brazil
Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil
São Paulo-Santa Casa Medical School, São Paulo, Brazil
... and 57 other locations.
Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy
Status: Recruiting
Last Changed: Apr 23, 2019
First Received: Jun 26, 2018
Disease(s): Lymphoma, B-Cell
Intervention(s): nivolumab
Locations: Sheba medical organization, Ramat Gan, Israel
Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma
Status: Not yet recruiting
Last Changed: Dec 14, 2016
First Received: Dec 14, 2016
Disease(s): Lymphoma, B Cell
Intervention(s): IL-2 pre-treated CD19 cells, IL-7/IL-15 pre-treated CD19 cells
Locations: First People's Hospital of Changzhou, Changzhou, Jiangsu, China
Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma
Status: Recruiting
Last Changed: Nov 15, 2019
First Received: Nov 14, 2019
Disease(s): Lymphoma, B-Cell
Intervention(s): CD19-PD1-CART Cell
Locations: Hai Nan Hospital of Chinese PLA General Hospital, Sanya, Hainan, China
Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
Status: Recruiting
Last Changed: Feb 02, 2018
First Received: Sep 07, 2016
Disease(s): Chronic Lymphocytic Leukemia, B-cell Lymphomas
Intervention(s): DTRMWXHS-12
Locations: Peking University Cancer Hospital, Beijing, China